Definition, diagnosis and classification of diabetes mellitus and its complications

Author(s): Alberti KG, Zimmet PZ

Abstract

The classification of diabetes mellitus and the tests used for its diagnosis were brought into order by the National Diabetes Data Group of the USA and the second World Health Organization Expert Committee on Diabetes Mellitus in 1979 and 1980. Apart from minor modifications by WHO in 1985, little has been changed since that time. There is however considerable new knowledge regarding the aetiology of different forms of diabetes as well as more information on the predictive value of different blood glucose values for the complications of diabetes. A WHO Consultation has therefore taken place in parallel with a report by an American Diabetes Association Expert Committee to re-examine diagnostic criteria and classification. The present document includes the conclusions of the former and is intended for wide distribution and discussion before final proposals are submitted to WHO for approval. The main changes proposed are as follows. The diagnostic fasting plasma (blood) glucose value has been lowered to > or =7.0 mmol l(-1) (6.1 mmol l(-1)). Impaired Glucose Tolerance (IGT) is changed to allow for the new fasting level. A new category of Impaired Fasting Glycaemia (IFG) is proposed to encompass values which are above normal but below the diagnostic cut-off for diabetes (plasma > or =6.1 to <7.0 mmol l(-1); whole blood > or =5.6 to <6.1 mmol l(-1)). Gestational Diabetes Mellitus (GDM) now includes gestational impaired glucose tolerance as well as the previous GDM. The classification defines both process and stage of the disease. The processes include Type 1, autoimmune and non-autoimmune, with beta-cell destruction; Type 2 with varying degrees of insulin resistance and insulin hyposecretion; Gestational Diabetes Mellitus; and Other Types where the cause is known (e.g. MODY, endocrinopathies). It is anticipated that this group will expand as causes of Type 2 become known. Stages range from normoglycaemia to insulin required for survival. It is hoped that the new classification will allow better classification of individuals and lead to fewer therapeutic misjudgements.

Similar Articles

Visfatin/PBEF and Atherosclerosis-Related Diseases

Author(s): Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP

Age of onset and type of diabetes

Author(s): Laakso M, Pyorala K

Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients

Author(s): Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, et al.

Leptin increase is associated with markers of the hemostatic system in obese healthy women

Author(s): Guagnano MT, Romano M, Falco A, Nutini M, Marinopiccoli M, et al.

Effect of exercise training on plasma visfatin and eotaxin levels

Author(s): Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, et al.

Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children

Author(s): Araki S, Dobashi K, Kubo K, Kawagoe R, Yamamoto Y, et al.

An evaluation of visfatin levels in obese subjects

Author(s): Kaminska A, Kopczynska E, Bronisz A, Zmudzinska M, Bielinski M, et al.

Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding

Author(s): Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, et al.

Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass

Author(s): García-Fuentes E, García-Almeida JM, García-Arnés J, García-Serrano S, Rivas-Marín J, et al.

The visfatin gene is associated with glucose and lipid metabolism in a Chinese population

Author(s): Jian WX, Luo TH, Gu YY, Zhang HL, Zheng S et al.

Serum visfatin increases with progressive beta-cell deterioration

Author(s): López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, Recasens M, Esteve E, et al.

Adipose tissue as an endocrine organ

Author(s): Kershaw EE, Flier JS

Obesity, hypertension and insulin resistance

Author(s): Sharma AM, Chetty VT

Regulation of adipocytokines and insulin resistance

Author(s): Fasshauer M, Paschke R